Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

Key Takeaways

• Eli Lilly will acquire Verve for roughly $1 billion

• Verve is developing a one-time gene-editing treatment for heart disease

• The company's lead drug, Verve-102, targets a gene linked to high cholesterol